Emergent BioSolutions Secures $56 Million U.S. Government Contract for Smallpox and Mpox Vaccine
Reuters
Sep 12
Emergent BioSolutions Secures $56 Million U.S. Government Contract for Smallpox and Mpox Vaccine
Emergent BioSolutions Inc. has announced a $56 million contract modification with the U.S. government for the supply of its ACAM2000® vaccine, intended for smallpox and mpox immunization. Deliveries are slated to begin this month, bringing projected annual sales for the vaccine and related products to over $120 million. The contract reflects the ongoing collaboration between Emergent and the government to enhance public health preparedness. ACAM2000® is a single-dose vaccine, approved by the FDA for individuals at high risk of smallpox and mpox infection, and is stockpiled both in the U.S. and internationally. This agreement is part of Emergent's existing 10-year contract with the U.S. Department of Health and Human Services.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000188), on September 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.